… this study was to compare the efficacy of gefitinib and erlotinib … In this study, we retrospectively
evaluated the difference in … The aim of the study was to identify clinical predictors to …

… No study has compared these two generations of EGFR-TKIs in this patient population. Herein,
we conducted a retrospective study to assess the efficacy of gefitinib/erlotinib … Clinical trial …

… Both docetaxel and pemetrexed were cytotoxic drugs, and both erlotinib and gefitinib
were EGFR-TKIs. Several randomized controlled trials indicated that EGFR-TKI gefitinib had …

… Restrictions on time points of outcome measurements and clinical settings were not imposed.
Article type was limited to randomized controlled trials. Published articles were searched …

… We considered all phase II/III randomized controlled trials in … randomized to receive gefitinib
or erlotinib (experimental arms) vs. chemotherapy, placebo, or best supportive care (control …

… A validated shorter term surrogate end point would reduce drug development costs and
allow for more rapid completion of randomized controlled trials. From such a point of view, some …

… randomized controlled trials comparing EGFR TKIs were published recently. CTONG 0901,
comparing first-line erlotinib to gefitinib in … similar between erlotinib-treated or gefitinib-treated …

… single-agent placebo controlled phase III trials of EGFR TKIs, … However, both studies
suggested that high EGFR gene copy … response/survival to erlotinib/gefitinib therapy. We believe …

… gefitinib failed to show noninferiority to docetaxel in the V15-32 trial, we investigated the
efficacy and tolerability of erlotinib … , based on data from previous clinical trials. The present …

… gefitinib versus erlotinib 0.96 (95% CI 0.69–1.34), gefitinib … to the arm which they were
originally randomized to. We also … or the clinical trials registers of Asian countries, to verify study …